Latest Updates…
The NCPE recommends that peg-IRI + 5FU + LV not be considered for reimbursement*.
The NCPE recommends that brentuximab vedotin be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*
Press Release HAG EUNETHTA21 – Professor Michael Barry, Director of the National Centre for Pharmacoeconomics joins the inaugural Heads of Agency Group.
https://www.ncpe.ie/research/covid-19/
The NCPE recommend that darolutamide (Nubeqa®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
The NCPE recommends that venetoclax in combination with obinutuzumab be considered for reimbursement.*
The NCPE recommends that risankizumab (Skyrizi®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
Following NCPE assessment of the Applicant’s submission, cost effectiveness of ruxolitinib (Jakavi®) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement unless cost-effectiveness can be improved relative to existing treatments.
The NCPE recommends that Sativex® not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.